Lundbeck’s Global Pricing Position

Lundbeck acknowledges the challenges faced by healthcare systems under pressure from rising demands and we recognize concerns expressed on the affordability of innovative medicines.

Committed to brain health
Lundbeck is the only global pharmaceutical company solely focused on psychiatric and neurological disorders. We have been focusing our research and innovation in this area for over 70 years. Given the high-risk nature of this work, many other companies have reduced their investments or even abandoned research in this field. Recent analyses have shown that the number of psychopharmacological drugs research programs in larger drug firms has shrunk by 70% in the past decade. As expressed in our strategy, Lundbeck remains committed to psychiatric and neurological disorders because the need for new treatments is so significant.

Reinvesting in future availability of new and better treatments
Our development and commercialization of improved treatments create value for patients, societies and investors. Running a sustainable business requires us to invest in new and better treatments for patients, while reducing the burden for patients and societies and delivering a competitive return to our shareholders. In short, the value our marketed medicines generate allows us to reinvest in research and development of new and better medicines.

Making medicines accessible and reducing the burden
The way healthcare systems are organized varies significantly around the world. Our dialogue with pricing authorities reflects this complexity and is always conducted in consideration of the relevant context.

As we continue to advance brain science and deliver transformative therapies, we recognize our innovations are meaningless if people cannot afford them. We have a responsibility to not just develop treatments and cures, but to also help patients access them. To ensure that we are working with governments and healthcare systems to find solutions to make medicines accessible and healthcare more sustainable, whilst securing future medical innovation. For instance, in USA, where patients take part in paying for their healthcare, the healthcare can fall short for people who are either uninsured or underinsured, which impacts their access to necessary medications.

Through a variety of initiatives, we work to reduce the burden and provide appropriate assistance to people who depend upon Lundbeck’s therapies. These include:

- Patient Assistance Programmes that provides free medicine to eligible patients who are uninsured or do not have insurance coverage for their medication
- Access-related support services for qualified patients who have insurance, but may require additional support, including benefit verifications and co-pay assistance
- Supporting reforms that make medicines more affordable e.g. ensuring that savings from rebates negotiated by health insurers are passed along to patients at the pharmacy counter